[{"address1": "Uppsalalaan 17", "address2": "3rd & 4th floor", "city": "Utrecht", "zip": "3584 CT", "country": "Netherlands", "phone": "31 30 253 8800", "website": "https://www.merus.nl", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.", "fullTimeEmployees": 172, "companyOfficers": [{"maxAge": 1, "name": "Dr. Sven Ante Lundberg M.D.", "age": 61, "title": "CEO, President & Executive Director", "yearBorn": 1963, "fiscalYear": 2023, "totalPay": 1114527, "exercisedValue": 0, "unexercisedValue": 10252539}, {"maxAge": 1, "name": "Mr. Gregory D. Perry", "age": 64, "title": "Chief Financial Officer", "yearBorn": 1960, "fiscalYear": 2023, "totalPay": 419102, "exercisedValue": 0, "unexercisedValue": 801494}, {"maxAge": 1, "name": "Mr. Peter B. Silverman J.D.", "age": 46, "title": "EVP, Company Secretary, COO, General Counsel, Chief Intellectual Property Officer & Head of US Legal", "yearBorn": 1978, "fiscalYear": 2023, "totalPay": 781842, "exercisedValue": 565022, "unexercisedValue": 1331558}, {"maxAge": 1, "name": "Dr. Hennie  Hoogenboom", "title": "Co-Founder and Scientific Advisor", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Harry  Shuman", "title": "Chief Accounting Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Cornelis Adriaan de Kruif Ph.D.", "age": 59, "title": "CTO & Executive VP", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 333530, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Cecilia Anna Wilhelmina Geuijen Ph.D.", "title": "Chief Scientific Officer & Senior VP", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kathleen  Farren", "title": "IR & Corporate Communications Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Audrey  Bergan", "title": "Chief People Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Shannon  Campbell", "age": 58, "title": "Executive VP & Chief Commercial Officer", "yearBorn": 1966, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 42.23, "open": 41.83, "dayLow": 41.38, "dayHigh": 47.75, "regularMarketPreviousClose": 42.23, "regularMarketOpen": 41.83, "regularMarketDayLow": 41.38, "regularMarketDayHigh": 47.75, "beta": 1.125, "forwardPE": -11.599608, "volume": 1773721, "regularMarketVolume": 1773721, "averageVolume": 535608, "averageVolume10days": 462960, "averageDailyVolume10Day": 462960, "bid": 43.7, "ask": 44.54, "bidSize": 100, "askSize": 100, "marketCap": 3002132992, "fiftyTwoWeekLow": 31.27, "fiftyTwoWeekHigh": 61.61, "priceToSalesTrailing12Months": 83.5504, "fiftyDayAverage": 45.8012, "twoHundredDayAverage": 49.288, "currency": "USD", "enterpriseValue": 2380910336, "floatShares": 62897584, "sharesOutstanding": 68463696, "sharesShort": 9779931, "sharesShortPriorMonth": 8759717, "sharesShortPreviousMonthDate": 1731628800, "dateShortInterest": 1734048000, "sharesPercentSharesOut": 0.1428, "heldPercentInsiders": 0.020299999, "heldPercentInstitutions": 1.06068, "shortRatio": 15.18, "shortPercentOfFloat": 0.1436, "impliedSharesOutstanding": 68463696, "bookValue": 10.278, "priceToBook": 4.266394, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -244556000, "trailingEps": -4.03, "forwardEps": -3.9, "enterpriseToRevenue": 66.262, "enterpriseToEbitda": -10.422, "52WeekChange": 0.30389535, "SandP52WeekChange": 0.22263205, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "MRUS", "underlyingSymbol": "MRUS", "shortName": "Merus N.V.", "longName": "Merus N.V.", "firstTradeDateEpochUtc": 1463664600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "42321671-9233-3f73-a2ee-487472589127", "messageBoardId": "finmb_24929296", "gmtOffSetMilliseconds": -18000000, "currentPrice": 43.85, "targetHighPrice": 109.0, "targetLowPrice": 67.0, "targetMeanPrice": 86.07143, "targetMedianPrice": 86.5, "recommendationKey": "none", "numberOfAnalystOpinions": 14, "totalCash": 632268032, "totalCashPerShare": 9.235, "ebitda": -228456992, "totalDebt": 11046000, "quickRatio": 7.944, "currentRatio": 8.321, "totalRevenue": 35932000, "debtToEquity": 1.571, "revenuePerShare": 0.584, "returnOnAssets": -0.21595, "returnOnEquity": -0.44601002, "freeCashflow": -109096128, "operatingCashflow": -155524992, "revenueGrowth": 0.067, "operatingMargins": -6.1359196, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-01-11"}]